Reach Us +44-1753390542
The Scourge of Antibody Mediated Rejection in Renal Transplantation
ISSN: 2161-0991

Journal of Transplantation Technologies & Research
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

The Scourge of Antibody Mediated Rejection in Renal Transplantation

Lavjay Butani*
Chief Pediatric Nephrology, University of California, USA
*Corresponding Author: Lavjay Butani, Professor of Pediatrics, Chief Pediatric Nephrology, University of California, Davis 2516 Stockton Blvd. Room 348 Sacramento, CA 95817, USA, Tel: 916-734-8118, Fax: 916-734-0629, Email: [email protected]

Received Date: Jan 29, 2018 / Accepted Date: Feb 05, 2018 / Published Date: Feb 06, 2018


The past decade has been witness to significant successes in effective strategies to prevent and treat cell-mediated rejection after renal transplantation, both in adults and in children, such that acute rejection rates have declined considerably [1]. This however, has not translated into improved long-term graft survival due to a variety of factors. One of these is the increasing recognition of antibodies as a major player in contributing to graft injury. Antibody mediated rejection is much harder to treat, especially if its diagnosis and recognition are delayed, and not infrequently leads to allograft loss; moreover, conventional therapies remain quite invasive and are associated with significant toxicity [2]. Many newer strategies are under investigation to address this need, including eculizumab and bortezomib, to name a few. Similar to other centers, in our own small experience, the use of bortezomib has been somewhat effective in reducing donor specific antibodies, and increasing rejection, albeit with greater success in the setting of early antibody mediated rejection [3]. Until now, randomized control trials using this potentially exciting agent, have been lacking. A recent study, the BORTEJECT Trial [4], is one study that moves us one step towards bridging this gap. Results from this study, a randomized trial of bortezomib in late (after 6 months) antibody mediated rejection were disappointing, in that the use of this agent was not associated with improvements in GFR, the slope of decline of the GFR, or in graft survival. Toxicities, were, however, encountered in the treatment arm. Data, on the use of eculizumab for treating antibody mediated rejection are even more limited. In 2016, a case report in a 61-year-old renal transplant recipient first highlighted the possible role for this agent in refractory rejection [5]; following failure of standard therapy, 5 doses of eculizumab were administered and resulted in dramatic improvement in renal function such that the patient became dialysis free. Its role, however, remains controversial, not only with respect to its efficacy [6], but also because of his potential toxicities and expense. While limited in scope because of the small patient numbers, anecdotal nature of these reports and the limited choices investigators had in one of the studies in adjusting immunosuppression, these data do highlight the need for more robust and controlled trials for newer agents that are being considered for introduction into the armamentarium that transplant providers can use to try to improve long-term graft function and survival. A recent meta-analysis and systematic review reinforced the lack of clarity with respect to the role of bortezomib and eculizumab in the treatment of antibody mediated rejection [7]. The time is ripe for collaborative studies to help improve the quality of life for transplant recipients.


Citation: Butani L (2018) The Scourge of Antibody Mediated Rejection in Renal Transplantation. J Transplant Technol Res 8: e138. DOI: 10.4172/2161-0991.1000e138

Copyright: © 2018 Butani L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 3204
  • [From(publication date): 0-2018 - Oct 17, 2019]
  • Breakdown by view type
  • HTML page views: 3117
  • PDF downloads: 87